BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 21, 2008
View Archived Issues
PDL Could Get $1.2B from BMS for Two Early Stage Antibodies
After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. (BioWorld Today)
Read More
Myriad Considers Splitting Itself After Flurizan Flop
Read More
Neurogenesis 'Funnel': Where Antidepressants Converge
Read More
Aposense Raises $13.3M for Apoptosis Technology
Read More
Other News To Note
Read More
Clinic Roundup
Read More